Korro Bio (KRRO) Interest & Investment Income (2019 - 2026)
Korro Bio's (KRRO) quarterly Interest & Investment Income came in at -$224000.0 in Q1 2026, down 7366.67% YoY from $3082.6 in Q1 2025, and down 7566.67% on a QoQ basis from $3000.0 in Q4 2025.
Korro Bio (KRRO) Interest & Investment Income (2019 - 2026) Analysis & Trends
Korro Bio (KRRO) has 8 years of Interest & Investment Income data on file, last reported at -$224000.0 in Q1 2026.
- Quarterly Interest & Investment Income fell 7366.67% year-over-year to -$224000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$247000.0 (down 236.46% YoY) and the FY2025 annual result came in at -$26000.0, down 114.13% from the prior year.
- Interest & Investment Income slipped to -$224000.0 in Q1 2026, from $3000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $593000.0 in Q3 2024 to a low of -$430000.0 in Q4 2024.
- A 5-year average of $127071.4 and a median of $34500.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 456.1% — and 2024, when it slumped 8500.0%.
- Tracing KRRO's Interest & Investment Income over 5 years: stood at $456000.0 in 2022, then plunged by 101.1% to -$5000.0 in 2023, then tumbled by 8500.0% to -$430000.0 in 2024, then surged by 100.7% to $3000.0 in 2025, then slumped by 7566.67% to -$224000.0 in 2026.
- The last three Interest & Investment Income figures came in at -$224000.0 (Q1 2026), $3000.0 (Q4 2025), and $48000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Korro Bio | 231.77 Mn | 116.73 Mn | - | -203,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -203,000.00 |
| Mar 31, 2026 | -224,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | 48,000.00 |
| Jun 30, 2025 | -74,000.00 |
| Mar 31, 2025 | -3,000.00 |
| Dec 31, 2024 | -430,000.00 |
| Sep 30, 2024 | 593,000.00 |
| Jun 30, 2024 | 21,000.00 |
| Dec 31, 2023 | -5,000.00 |
| Mar 31, 2023 | 523,000.00 |
| Dec 31, 2022 | 456,000.00 |
| Sep 30, 2022 | 351,000.00 |
| Jun 30, 2022 | 425,000.00 |
| Mar 31, 2022 | 95,000.00 |
| Dec 31, 2021 | 82,000.00 |
| Sep 30, 2021 | 172,000.00 |
| Jun 30, 2021 | 118,000.00 |
| Mar 31, 2021 | 25,000.00 |
| Dec 31, 2020 | 32,000.00 |